Under the agreement Mr Velardi will continue the development on the selective depletion of allo-reactive T-cells from mismatched donors using Kiadis Pharma’s Atir.
Kiadis Pharma is preparing for a multi-center pivotal study on Atir to start in early 2009 and Mr Velardi will participate in this upcoming study.
Manja Bouman, CEO of Kiadis Pharma, said: “We are very pleased with our continued collaboration with the University of Perugia and professor Velardi, who is a leader in the field of mismatched bone marrow transplantations. This collaboration is an important milestone in the development of Atir as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients.”